Furthermore, PD-1/PD-L1 inhibitors have already been approved by the Food and Drug Administration (FDA) for treating melanoma, non-small cell lung cancer (NSCLC) and other malignancies [6]. Here, CD274 is linked to non-small cell lung carcinoma.